Drugs and biologics hearings before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fourth Congress, first session, May 25, 1995-a consumer's perspective, June 19, 1995-FDA review process.

Similar Items

• Drugs and biologics hearings before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fourth Congress, first session, May 25, 1995-a consumer's perspective, June 19, 1995-FDA review process.
  Published: (1995)
• Drugs and biologics : hearings before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fourth Congress, first session, May 25, 1995-a consumer's prespective, June 19, 1995-FDA review process.
  Published: (1995)
• Drug bioequivalence a report of the Office of Technology Assessment, Drug Bioequivalence Study Panel.
• Drug bioequivalence : a report of the Office of Technology Assessment, Drug Bioequivalence Study Panel.
• Oversight of the new drug review process and FDA's regulation of Merital hearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-ninth Congress, second session, May 22, 1986.
  Published: (1987)